Shanghai, China – Following the milestone of completing its 1,000th implant outside China, MicroPort CardioFlow's VitaFlow^® series has achieved another significant breakthrough in the strategic Middle East market: the VitaFlow Liberty^® system has received market approval in the United Arab Emirates (Application No: DRCLAS-2025-006384). After Turkey and Saudi Arabia, the UAE has become another key hub for MicroPort CardioFlow in the region, further extending its rapid global expansion momentum.

As a medical benchmark in the Middle East, the UAE maintains extremely stringent approval processes for innovative medical technologies. The market access achieved by VitaFlow Liberty^® serves as strong testimony to the product's exceptional performance and reliable quality.

Since obtaining EU CE MDR certification in 2024, the globalization of VitaFlow Liberty^® has entered a phase of explosive growth, achieving "multiple breakthroughs" across Europe, Latin America, and Asia:

• In Europe, nearly 300 clinical applications have been completed across nearly 10 countries including Switzerland, Italy, Denmark, Spain, Poland, and Greece.

• In Latin America, market presence has been established in the top five economies - Brazil, Mexico, Argentina, Colombia, and Chile - as well as in Ecuador and Panama.

• In Asia, market access has been secured in several Middle Eastern markets including Saudi Arabia and the UAE, with the first commercial applications completed in South Korea, Turkey, and India.

To date, the VitaFlow^® series TAVI products have reached 32 countries and regions worldwide, entered 800 core hospitals, and treated more than 17,000 patients with aortic valve disease. In the future, MicroPort^® CardioFlow will accelerate its globalization efforts, bringing more high-end medical devices that combine exceptional quality with cutting-edge innovation to the global market. The company is committed to providing superior comprehensive medical solutions for patients with structural heart disease.